Valuation: Intensity Therapeutics, Inc.

Capitalization 13.52M 11.48M 10.6M 9.99M 18.53M 1.26B 18.86M 124M 48.68M 605M 50.7M 49.64M 2.15B P/E ratio 2026 *
-1.28x
P/E ratio 2027 * -1.21x
Enterprise value 13.52M 11.48M 10.6M 9.99M 18.53M 1.26B 18.86M 124M 48.68M 605M 50.7M 49.64M 2.15B EV / Sales 2026 *
-
EV / Sales 2027 * 38.5x
Free-Float
56.98%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Intensity Therapeutics, Inc.

1 day+0.47%
1 week-1.46%
Current month-7.82%
1 month-16.49%
3 months-45.71%
6 months-16.90%
Current year-47.15%
1 week 5.14
Extreme 5.14
5.62
1 month 5.08
Extreme 5.08
6.57
Current year 5.08
Extreme 5.08
11.07
1 year 4.63
Extreme 4.6325
48.56
3 years 4.63
Extreme 4.6325
286
5 years 4.63
Extreme 4.6325
286
10 years 4.63
Extreme 4.6325
286
Manager TitleAgeSince
Chief Executive Officer 67 01/04/2012
Director of Finance/CFO 56 11/12/2023
Director of Finance/CFO 67 01/06/2023
Director TitleAgeSince
Chairman 67 01/04/2012
Director/Board Member 60 01/06/2016
Director/Board Member 65 01/05/2018
Change 5d. change 1-year change 3-years change Capi.($)
+1.88%-1.46%-88.28% - 13.52M
+0.94%+5.17%+0.45%-8.23% 47.35B
+1.55%+5.18%+41.01%+23.00% 35.57B
-0.33%+54.62%+305.60%+506.84% 31.16B
+3.52%+6.31%+23.62%-12.20% 28.86B
-0.72%+2.98%+35.64%+28.89% 29.62B
+0.19%+1.55%+47.22%+193.61% 15.01B
+0.26%+4.74%+74.46%+164.37% 14.73B
-2.60%+2.78%+3,765.33%+3,966.45% 15.12B
+0.87%+8.85%+40.89%+13.56% 14.34B
Average +0.28%+8.70%+424.59%+541.81% 23.18B
Weighted average by Cap. +0.56%+11.27%+310.86%+354.70%

Financials

2026 *2027 *
Net sales - 351K 298K 275K 259K 481K 32.66M 490K 3.23M 1.26M 15.71M 1.32M 1.29M 55.87M
Net income -11.8M -10.02M -9.25M -8.72M -16.18M -1.1B -16.46M -108M -42.5M -528M -44.27M -43.34M -1.88B -13.65M -11.59M -10.7M -10.09M -18.72M -1.27B -19.04M -125M -49.17M -611M -51.21M -50.14M -2.17B
Net Debt - -
Logo Intensity Therapeutics, Inc.
Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company. The Company is engaged in developing treatments that address both the regional and systemic nature of a patient’s cancer. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its lead investigational product candidate, INT230-6, is designed for direct intratumoral injection. Its INT230-6 is primarily comprised of three components: cisplatin, vinblastine sulfate and an amphiphilic molecule (SHAO) which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection. Its pipeline consists of Phase III open-label, randomized study testing the superiority of INT230-6 used as monotherapy compared to the standard of care drugs in 2nd and 3rd line treatment for certain soft tissue sarcoma subtypes, and Phase II/III clinical study in metastatic triple negative breast cancer.
Employees
6
Date Price Change Volume
17/04/26 5.420 $ +1.88% 14,492
16/04/26 5.320 $ +0.38% 29,849
15/04/26 5.300 $ -1.12% 24,300
14/04/26 5.360 $ -1.83% 26,568
13/04/26 5.460 $ -0.73% 21,252
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
5.320USD
Average target price
41.50USD
Spread / Average Target
+680.08%

Quarterly revenue - Rate of surprise